(?R,?S)-?-[[(1,1-Dimethylethoxy)carbonyl]amino]-?-hydroxybenzenepropanoic Acid (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(Acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4,6-dimethoxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester; TXD 258; XRP 6258; ?-[[(1,1-Dimethylethoxy)carbonyl]amino]-?-hydroxybenzenepropanoic Acid [2aR-[2a?,4?,4a?,6?,9?(?R*,?S*),11?,12?,12a?,12b?]]-12b-(Acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4,6-dimethoxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester
Cabazitaxel is a fully characterized chemical compound used as a reference standard of API Cabazitaxel. The standard offered is compliant with regulatory guidelines. Cabazitaxel is used for analytical method development, method validation (AMV), and Quality Controlled (QC) applications during synthesis and formulation stages of drug development and serves as a reference standard for traceability against pharmacopeial standards (USP or EP). Axios Research products are intended for analytical purposes only and are not for human use. CAS - 183133-96-2
